Last reviewed 2026-04-22 · How we verify

Nebivolol+Diltiazem

Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload.

Nebivolol and diltiazem work together as a beta-blocker and calcium channel blocker to reduce heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Atrial fibrillation.

At a glance

Mechanism of action

Nebivolol is a selective beta-1 adrenergic receptor antagonist with vasodilatory properties that reduces heart rate and contractility. Diltiazem is a non-dihydropyridine calcium channel blocker that slows atrioventricular node conduction and causes vasodilation. The combination provides additive cardiovascular effects for blood pressure control and heart rate reduction.

Approved indications

• Hypertension
• Angina pectoris
• Atrial fibrillation

Common side effects

• Bradycardia
• Dizziness
• Fatigue
• Constipation
• Headache
• Hypotension

Key clinical trials

• Rate Control in Patients With Atrial Fibrillation (NA)
• Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging (PHASE2)
• Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
• ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
• The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm (PHASE4)
• Treatment of Supine Hypertension in Autonomic Failure (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nebivolol+Diltiazem CI brief — competitive landscape report
• Nebivolol+Diltiazem updates RSS · CI watch RSS
• Korea University Anam Hospital portfolio CI